Ocugen, Inc.
NASDAQ:OCGNBiotechnology
Healthcare
$0.74 +2.46%
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
52W Low $0.90High $2.73
Volume 5.83M
Average 7.51M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$56.96M
FY 2025 · Annual
Investing Cash Flow
-$311,000.00
FY 2025 · Annual
Financing Cash Flow
$17.33M
FY 2025 · Annual
-73.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| Deferred Income Tax | (52K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.96M | 10.54M | 9.22M | 7.43M | 7.71M |
| Change in Working Capital | 2.49M | 9.2M | (13.16M) | 3.67M | (523K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.5M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.01M) | 9.2M | (13.16M) | 3.67M | (523K) |
| Other Non-Cash Items | 799K | 6.51M | 4.26M | (1.15M) | 1.31M |
| Operating Cash Flow | (47.94M) | (60.08M) | (62.05M) | (42.14M) | (56.96M) |
| Capital Expenditures | (939K) | (4.46M) | (10.48M) | (3.39M) | (185K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (13.27M) | (3.95M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 17.5M | 0 | 0 |
| Other Investing Activities | (877K) | 761K | 0 | 0 | (126K) |
| Investing Cash Flow | (1.82M) | (16.97M) | 3.08M | (3.39M) | (311K) |
| Debt Repayment | (10K) | 500K | 500K | 30M | (1M) |
| Common Stock Issued | 129.21M | 59.57M | 20.8M | 38.56M | 18.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.53M) | (592K) | (68K) | (3.7M) | 0 |
| Financing Cash Flow | 120.68M | 59.48M | 20.88M | 64.86M | 17.33M |
| Effect of Forex Changes | (325) | 25K | (5K) | 28K | 13K |
| Net Change in Cash | 70.92M | (17.55M) | (38.1M) | 19.36M | (39.93M) |
| Free Cash Flow | (48.88M) | (64.54M) | (72.53M) | (45.53M) | (57.15M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$67.8M
+ D&A$2.4M
+ Stock-Based Comp$7.7M
+ Deferred Tax$0
- Working Capital-$523.0K
+ Other Non-Cash$1.3M
= Operating Cash Flow-$57.0M
- Capex-$185.0K
= Free Cash Flow-$57.1M
Analysis
FY2025 free cash flow is -$57.1M. FCF conversion is 84.2% of net income. Operating cash flow was -$57.0M, with capex of -$185.0K. The largest bridge item is Stock-Based Comp at $7.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| DEFA14A | DEFA14A filing | Nov 6, 2026 | |
| DEFA14A | DEFA14A filing | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 |
Does OCGN generate free cash flow?
Ocugen, Inc. (OCGN) generated -$57.15M of free cash flow in fiscal 2025.
How much operating cash flow does OCGN produce?
Operating cash flow was -$56.96M, before capital expenditures of $185,000.00.
Continue the stock analysis
Jump to another research area for this company.